Company intelligence / Profile preview

1910 Genetics

Boston, Massachusetts, United States1910genetics.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

1910 Genetics has developed a proprietary multimodal AI-driven drug discovery platform integrating computational data and laboratory automation. The company has launched CANDID-CNS™, an AI model for predicting blood-brain barrier permeability that outperforms industry standards. No clinical-stage results have been reported yet; the pipeline is in preclinical development[5][6].

Therapeutic areas: OncologyImmunologyNeurologyHematology
Modalities: Small moleculesLarge molecules (including protein therapeutics)
Industry: Biotech

Drug pipeline

1 asset

1910-102

Preclinical

Partnerships

Microsoft (five-year commercial agreement for R&D productivity with AI tools)[2]Accenture Ventures/Accenture[8]

Beyond the preview

Go deeper on 1910 Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1910 Genetics.

Explore the full profile